HER3-DXd + HER3-DXd + Osimertinib + Osimertinib + HER3-DXd + HER3-DXd + Osimertinib
Phase 1Active 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Non-Small Cell Lung Cancer (NSCLC)
Conditions
Non-Small Cell Lung Cancer (NSCLC)
Trial Timeline
Jun 11, 2021 → Apr 30, 2027
NCT ID
NCT04676477About HER3-DXd + HER3-DXd + Osimertinib + Osimertinib + HER3-DXd + HER3-DXd + Osimertinib
HER3-DXd + HER3-DXd + Osimertinib + Osimertinib + HER3-DXd + HER3-DXd + Osimertinib is a phase 1 stage product being developed by Daiichi Sankyo for Non-Small Cell Lung Cancer (NSCLC). The current trial status is active. This product is registered under clinical trial identifier NCT04676477. Target conditions include Non-Small Cell Lung Cancer (NSCLC).
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04676477 | Phase 1 | Active |
Competing Products
20 competing products in Non-Small Cell Lung Cancer (NSCLC)